US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Spero Therapeutics Inc.

2.42

+0.12005.22%

Post-market: 2.38-0.0400-1.65%17:46 EST

Volume:1.03M

Turnover:2.44M

Market Cap:136.34M

PE:-3.06

High:2.43

Open:2.31

Low:2.31

Close:2.30

52wk High:3.22

52wk Low:0.5052

Shares:56.34M

Float Shares:45.80M

Volume Ratio:1.94

T/O Rate:2.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7905

EPS(LYR):-1.2688

ROE:-95.29%

ROA:-29.77%

PB:5.15

PE(LYR):-1.91

Loading ...

Overview Company News Filings

Spero Therapeutics CEO Ankit Mahadevia Resigns Effective January 2026

Spero Therapeutics to Receive $25 Million Milestone Payment Following Tebipenem HBr NDA Resubmission by GSK

Spero Therapeutics Announces FDA Review of Tebipenem HBr NDA Resubmission

Spero Therapeutics Inc - Nda Submission Triggers $25 Mln Milestone Payment to Spero

THOMSON REUTERS

Spero Announces Nda Resubmission of Tebipenem Hbr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

THOMSON REUTERS

Spero Therapeutics announces inducement grant under Nasdaq listing rule

Spero Therapeutics Grants 90,000 RSUs to New Employee Under Inducement Plan

Spero Therapeutics Q3 net loss narrows

BRIEF-Spero Therapeutics Q3 EPS USD -0.13

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

THOMSON REUTERS

Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment

BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr

GSK: to Work With U.S. Authorities to Include Tebipenem Hbr Data as Part of Filing in Q4

THOMSON REUTERS

GSK: Data Show Tebipenem Hbr’s Potential as First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections

THOMSON REUTERS

GSK: Full Results of Positive Pivotal Phase Iii Pivot-Po Trial Evaluating Tebipenem Hbr

THOMSON REUTERS

GSK: Safety Profile of Tebipenem Hbr Generally Similar to Imipenem-Cilastatin & Other Carbapenem Antibiotics

THOMSON REUTERS

GSK: Trial Primary Endpoint Met, Showing Non-Inferiority of Oral Tebipenem Hbr VS Iv Treatment

THOMSON REUTERS

Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025

Director Ankit Mahadevia Reports Disposal of Common Shares of Spero Therapeutics Inc

Timothy Keutzer, Chief Operating Officer, Reports Disposal of Spero Therapeutics Inc. Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","market":"US","secType":"STK","nameCN":"Spero Therapeutics Inc.","latestPrice":2.42,"timestamp":1770411600000,"preClose":2.3,"halted":0,"volume":1026366,"hourTrading":{"tag":"盘后","latestPrice":2.38,"preClose":2.42,"latestTime":"17:46 EST","volume":2792,"amount":6780.22,"timestamp":1770417971909,"change":-0.04,"changeRate":-0.016529,"amplitude":0.033058},"delay":0,"changeRate":0.052173913043478314,"floatShares":45804555,"shares":56339295,"eps":-0.790454,"marketStatus":"Market Closed","change":0.12,"latestTime":"02-06 16:00:00 EST","open":2.31,"high":2.43,"low":2.305,"amount":2439248.2981152,"amplitude":0.054348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.790454,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1509595200000,"exchange":"NASDAQ","adjPreClose":2.3,"preHourTrading":{"tag":"盘前","latestPrice":2.3135,"preClose":2.3,"latestTime":"09:29 EST","volume":1605,"amount":3759.271125,"timestamp":1770388176920,"change":0.0135,"changeRate":0.00587,"amplitude":0.139304},"postHourTrading":{"tag":"盘后","latestPrice":2.38,"preClose":2.42,"latestTime":"17:46 EST","volume":2792,"amount":6780.22,"timestamp":1770417971909,"change":-0.04,"changeRate":-0.016529,"amplitude":0.033058},"volumeRatio":1.937589,"impliedVol":0.8258,"impliedVolPercentile":0.4422},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","floatShares":45804555,"roa":"-29.77%","roe":"-95.29%","lyrEps":-1.268849,"volumeRatio":1.937589,"shares":56339295,"dividePrice":0,"high":2.43,"amplitude":0.054348,"preClose":2.3,"low":2.305,"week52Low":0.5052,"pbRate":"5.15","psRate":"3.36","week52High":3.22,"institutionHeld":0.1648,"latestPrice":2.42,"eps":-0.790454,"divideRate":0,"volume":1026366,"delay":0,"ttmEps":-0.790454,"open":2.31,"prevYearClose":2.33,"prevWeekClose":2.19,"prevMonthClose":2.19,"prevQuarterClose":2.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"SPRO","fiscalQuarterEnding":"2025/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-08-12","symbol":"SPRO","fiscalQuarterEnding":"2025/06","expectedEps":-0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-05-13","symbol":"SPRO","fiscalQuarterEnding":"2025/03","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-27","symbol":"SPRO","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2024-11-14","symbol":"SPRO","fiscalQuarterEnding":"2024/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1743138000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRO","date":"2026-02-05","current":-3.004602,"percent":0.403226,"low":-57.13681,"twenty":-5.888463,"median":-2.129376,"eighty":3.068078,"high":19.398721,"avg":-3.772302,"sd":12.479808,"marketCap":129016985},"quantilePoints":[{"date":"2021-02-12","current":-6.533525,"twenty":-5.332316,"median":-4.488361,"eighty":-3.38727,"marketCap":553265401},{"date":"2021-02-19","current":-6.594526,"twenty":-5.345052,"median":-4.491045,"eighty":-3.388835,"marketCap":558431024},{"date":"2021-02-26","current":-5.833619,"twenty":-5.361227,"median":-4.491318,"eighty":-3.396406,"marketCap":493996675},{"date":"2021-03-05","current":-5.246083,"twenty":-5.368258,"median":-4.500168,"eighty":-3.402401,"marketCap":444243570},{"date":"2021-03-12","current":-6.309418,"twenty":-5.371976,"median":-4.50969,"eighty":-3.412251,"marketCap":493901262},{"date":"2021-03-19","current":-5.981509,"twenty":-5.387929,"median":-4.516354,"eighty":-3.419748,"marketCap":468232558},{"date":"2021-03-26","current":-5.205082,"twenty":-5.390332,"median":-4.5202,"eighty":-3.42079,"marketCap":407453789},{"date":"2021-04-01","current":-5.382228,"twenty":-5.390408,"median":-4.521243,"eighty":-3.420837,"marketCap":421320789},{"date":"2021-04-09","current":-4.92994,"twenty":-5.390015,"median":-4.533574,"eighty":-3.422527,"marketCap":385915681},{"date":"2021-04-16","current":-4.873404,"twenty":-5.388431,"median":-4.546657,"eighty":-3.425372,"marketCap":381490043},{"date":"2021-04-23","current":-4.96763,"twenty":-5.385512,"median":-4.556667,"eighty":-3.42912,"marketCap":388866107},{"date":"2021-04-30","current":-5.186236,"twenty":-5.384138,"median":-4.561447,"eighty":-3.434848,"marketCap":405978576},{"date":"2021-05-07","current":-5.34766,"twenty":-5.383374,"median":-4.571125,"eighty":-3.437796,"marketCap":398106514},{"date":"2021-05-14","current":-5.550887,"twenty":-5.383374,"median":-4.577339,"eighty":-3.443639,"marketCap":413235748},{"date":"2021-05-21","current":-5.778023,"twenty":-5.388431,"median":-4.581276,"eighty":-3.449286,"marketCap":430144892},{"date":"2021-05-28","current":-5.778023,"twenty":-5.40792,"median":-4.591235,"eighty":-3.449342,"marketCap":430144892},{"date":"2021-06-04","current":-5.662462,"twenty":-5.417705,"median":-4.597317,"eighty":-3.449426,"marketCap":421541994},{"date":"2021-06-11","current":-6.144628,"twenty":-5.434813,"median":-4.599337,"eighty":-3.453071,"marketCap":457436844},{"date":"2021-06-18","current":-5.845765,"twenty":-5.446368,"median":-4.604387,"eighty":-3.468018,"marketCap":435187970},{"date":"2021-06-25","current":-5.944218,"twenty":-5.457323,"median":-4.615778,"eighty":-3.470102,"marketCap":442517290},{"date":"2021-07-02","current":-6.299275,"twenty":-5.46757,"median":-4.61859,"eighty":-3.472876,"marketCap":468949531},{"date":"2021-07-09","current":-6.287307,"twenty":-5.475294,"median":-4.622569,"eighty":-3.474158,"marketCap":468058556},{"date":"2021-07-16","current":-5.756716,"twenty":-5.489092,"median":-4.626391,"eighty":-3.480666,"marketCap":428558691},{"date":"2021-07-23","current":-5.716821,"twenty":-5.500087,"median":-4.638695,"eighty":-3.480666,"marketCap":425588776},{"date":"2021-07-30","current":-5.32187,"twenty":-5.502843,"median":-4.646898,"eighty":-3.488476,"marketCap":396186620},{"date":"2021-08-06","current":-6.019339,"twenty":-5.513362,"median":-4.65834,"eighty":-3.4903,"marketCap":454556416},{"date":"2021-08-13","current":-5.755408,"twenty":-5.525665,"median":-4.663304,"eighty":-3.4903,"marketCap":434625371},{"date":"2021-08-20","current":-6.581258,"twenty":-5.533309,"median":-4.666253,"eighty":-3.49108,"marketCap":496990254},{"date":"2021-08-27","current":-7.219801,"twenty":-5.546817,"median":-4.67971,"eighty":-3.494402,"marketCap":545210525},{"date":"2021-09-03","current":-7.624212,"twenty":-5.552096,"median":-4.686116,"eighty":-3.49605,"marketCap":575750029},{"date":"2021-09-10","current":-7.798748,"twenty":-5.562419,"median":-4.693364,"eighty":-3.499653,"marketCap":588930237},{"date":"2021-09-17","current":-8.152075,"twenty":-5.582179,"median":-4.697982,"eighty":-3.503388,"marketCap":615612120},{"date":"2021-09-24","current":-7.973283,"twenty":-5.594764,"median":-4.710228,"eighty":-3.509466,"marketCap":602110444},{"date":"2021-10-01","current":-7.470962,"twenty":-5.603316,"median":-4.715815,"eighty":-3.514862,"marketCap":564177164},{"date":"2021-10-08","current":-7.270885,"twenty":-5.619957,"median":-4.72441,"eighty":-3.518383,"marketCap":549068146},{"date":"2021-10-15","current":-7.245343,"twenty":-5.64147,"median":-4.72918,"eighty":-3.521658,"marketCap":547139335},{"date":"2021-10-22","current":-7.177232,"twenty":-5.657325,"median":-4.732389,"eighty":-3.522954,"marketCap":541995840},{"date":"2021-10-29","current":-7.475219,"twenty":-5.670933,"median":-4.736196,"eighty":-3.536236,"marketCap":564498633},{"date":"2021-11-05","current":-7.458191,"twenty":-5.687453,"median":-4.740792,"eighty":-3.542421,"marketCap":563212759},{"date":"2021-11-12","current":-6.86102,"twenty":-5.711236,"median":-4.749034,"eighty":-3.563973,"marketCap":542713529},{"date":"2021-11-19","current":-6.742515,"twenty":-5.718593,"median":-4.751989,"eighty":-3.576764,"marketCap":533339680},{"date":"2021-11-26","current":-6.174509,"twenty":-5.742633,"median":-4.762697,"eighty":-3.582625,"marketCap":488409852},{"date":"2021-12-03","current":-5.541121,"twenty":-5.745538,"median":-4.767707,"eighty":-3.588112,"marketCap":438308246},{"date":"2021-12-10","current":-5.569726,"twenty":-5.747863,"median":-4.770134,"eighty":-3.591569,"marketCap":440570899},{"date":"2021-12-17","current":-5.553381,"twenty":-5.745538,"median":-4.78812,"eighty":-3.601982,"marketCap":439277955},{"date":"2021-12-23","current":-5.729095,"twenty":-5.744668,"median":-4.791373,"eighty":-3.610941,"marketCap":453177110},{"date":"2021-12-31","current":-6.542283,"twenty":-5.752225,"median":-4.794534,"eighty":-3.616718,"marketCap":517501108},{"date":"2022-01-07","current":-5.353148,"twenty":-5.753772,"median":-4.807458,"eighty":-3.62158,"marketCap":423439382},{"date":"2022-01-14","current":-5.394012,"twenty":-5.752225,"median":-4.812969,"eighty":-3.626637,"marketCap":426671744},{"date":"2022-01-21","current":-4.740192,"twenty":-5.749384,"median":-4.815545,"eighty":-3.632464,"marketCap":374953957},{"date":"2022-01-28","current":-4.531787,"twenty":-5.746075,"median":-4.808831,"eighty":-3.647672,"marketCap":358468912},{"date":"2022-02-04","current":-4.343814,"twenty":-5.744835,"median":-4.802417,"eighty":-3.65681,"marketCap":343600048},{"date":"2022-02-11","current":-4.106805,"twenty":-5.743655,"median":-4.792518,"eighty":-3.669066,"marketCap":324852350},{"date":"2022-02-18","current":-3.783981,"twenty":-5.74156,"median":-4.791069,"eighty":-3.673506,"marketCap":299316693},{"date":"2022-02-25","current":-3.873881,"twenty":-5.741354,"median":-4.78527,"eighty":-3.672903,"marketCap":306427889},{"date":"2022-03-04","current":-3.518367,"twenty":-5.741354,"median":-4.7699,"eighty":-3.669563,"marketCap":278306342},{"date":"2022-03-11","current":-3.416208,"twenty":-5.737401,"median":-4.767881,"eighty":-3.646094,"marketCap":270225438},{"date":"2022-03-18","current":-3.42438,"twenty":-5.729095,"median":-4.765727,"eighty":-3.615008,"marketCap":270871910},{"date":"2022-03-25","current":-3.330394,"twenty":-5.720811,"median":-4.751989,"eighty":-3.585269,"marketCap":263437478},{"date":"2022-04-01","current":-2.594724,"twenty":-5.718038,"median":-4.749034,"eighty":-3.543147,"marketCap":232892024},{"date":"2022-04-08","current":-2.685959,"twenty":-5.716835,"median":-4.743166,"eighty":-3.523112,"marketCap":241080914},{"date":"2022-04-14","current":-2.229784,"twenty":-5.716824,"median":-4.739876,"eighty":-3.518367,"marketCap":200136465},{"date":"2022-04-22","current":-1.999871,"twenty":-5.713858,"median":-4.736196,"eighty":-3.503388,"marketCap":179500463},{"date":"2022-04-29","current":-1.773609,"twenty":-5.712894,"median":-4.732389,"eighty":-3.490924,"marketCap":159192016},{"date":"2022-05-06","current":-0.755426,"twenty":-5.711236,"median":-4.72918,"eighty":-3.48159,"marketCap":67804007},{"date":"2022-05-13","current":-0.624047,"twenty":-5.702858,"median":-4.72441,"eighty":-3.473837,"marketCap":56012005},{"date":"2022-05-20","current":-0.439054,"twenty":-5.700864,"median":-4.715815,"eighty":-3.449426,"marketCap":45293730},{"date":"2022-05-27","current":-0.394513,"twenty":-5.699193,"median":-4.710228,"eighty":-3.447094,"marketCap":40698714},{"date":"2022-06-03","current":-0.330882,"twenty":-5.690284,"median":-4.702589,"eighty":-3.433305,"marketCap":34134405},{"date":"2022-06-10","current":-0.340426,"twenty":-5.683482,"median":-4.696894,"eighty":-3.422991,"marketCap":35119052},{"date":"2022-06-17","current":-0.298366,"twenty":-5.682255,"median":-4.689296,"eighty":-3.417395,"marketCap":30780043},{"date":"2022-06-24","current":-0.299066,"twenty":-5.678341,"median":-4.684128,"eighty":-3.397857,"marketCap":30852251},{"date":"2022-07-01","current":-0.263242,"twenty":-5.671936,"median":-4.673321,"eighty":-3.386215,"marketCap":27156545},{"date":"2022-07-08","current":-0.262351,"twenty":-5.670421,"median":-4.665101,"eighty":-3.380277,"marketCap":27064645},{"date":"2022-07-15","current":-0.251343,"twenty":-5.668792,"median":-4.662662,"eighty":-3.355763,"marketCap":25929019},{"date":"2022-07-22","current":-0.239603,"twenty":-5.661665,"median":-4.658465,"eighty":-3.345397,"marketCap":24717904},{"date":"2022-07-29","current":-0.232953,"twenty":-5.658189,"median":-4.649834,"eighty":-3.332999,"marketCap":24031934},{"date":"2022-08-05","current":-0.271941,"twenty":-5.656983,"median":-4.638695,"eighty":-3.324822,"marketCap":28053981},{"date":"2022-08-12","current":-0.241477,"twenty":-5.656009,"median":-4.630492,"eighty":-3.298983,"marketCap":27352632},{"date":"2022-08-19","current":-0.304169,"twenty":-5.651859,"median":-4.622849,"eighty":-3.28605,"marketCap":34453796},{"date":"2022-08-26","current":-0.28064,"twenty":-5.646896,"median":-4.61859,"eighty":-3.259567,"marketCap":31788667},{"date":"2022-09-02","current":-0.224976,"twenty":-5.644127,"median":-4.615778,"eighty":-3.246458,"marketCap":25483535},{"date":"2022-09-09","current":-0.346737,"twenty":-5.640585,"median":-4.6058,"eighty":-3.222936,"marketCap":39275574},{"date":"2022-09-16","current":-0.278628,"twenty":-5.637707,"median":-4.599337,"eighty":-3.215126,"marketCap":31560729},{"date":"2022-09-23","current":-0.609885,"twenty":-5.631352,"median":-4.597547,"eighty":-3.190148,"marketCap":69082929},{"date":"2022-09-30","current":-0.619173,"twenty":-5.622753,"median":-4.591235,"eighty":-3.174978,"marketCap":70134954},{"date":"2022-10-07","current":-0.578927,"twenty":-5.619258,"median":-4.581276,"eighty":-3.159693,"marketCap":65576181},{"date":"2022-10-14","current":-0.612981,"twenty":-5.617086,"median":-4.577339,"eighty":-3.153712,"marketCap":69433604},{"date":"2022-10-21","current":-0.585118,"twenty":-5.607799,"median":-4.571125,"eighty":-3.144373,"marketCap":66277531},{"date":"2022-10-28","current":-0.609885,"twenty":-5.605826,"median":-4.563951,"eighty":-3.129215,"marketCap":69082929},{"date":"2022-11-04","current":-0.585118,"twenty":-5.602689,"median":-4.558235,"eighty":-3.117302,"marketCap":66277531},{"date":"2022-11-11","current":-0.750715,"twenty":-5.602457,"median":-4.550515,"eighty":-3.107707,"marketCap":85034954},{"date":"2022-11-18","current":-0.94528,"twenty":-5.602457,"median":-4.53616,"eighty":-3.104599,"marketCap":96821219},{"date":"2022-11-25","current":-0.970555,"twenty":-5.599889,"median":-4.531787,"eighty":-3.094731,"marketCap":99410021},{"date":"2022-12-02","current":-0.970555,"twenty":-5.598514,"median":-4.521243,"eighty":-3.082423,"marketCap":99410021},{"date":"2022-12-09","current":-0.88462,"twenty":-5.594581,"median":-4.519318,"eighty":-3.068818,"marketCap":90608092},{"date":"2022-12-16","current":-0.849235,"twenty":-5.593249,"median":-4.516004,"eighty":-3.045488,"marketCap":86983769},{"date":"2022-12-23","current":-0.80374,"twenty":-5.590343,"median":-4.507828,"eighty":-3.001981,"marketCap":82323924},{"date":"2022-12-30","current":-0.87451,"twenty":-5.587699,"median":-4.500168,"eighty":-2.925595,"marketCap":89572571},{"date":"2023-01-06","current":-0.909895,"twenty":-5.587699,"median":-4.491045,"eighty":-2.881897,"marketCap":93196895},{"date":"2023-01-13","current":-1.010994,"twenty":-5.587699,"median":-4.477497,"eighty":-2.7929,"marketCap":103552106},{"date":"2023-01-20","current":-0.950335,"twenty":-5.587699,"median":-4.466436,"eighty":-2.732909,"marketCap":97338979},{"date":"2023-01-27","current":-0.920005,"twenty":-5.587699,"median":-4.454324,"eighty":-2.67399,"marketCap":94232416},{"date":"2023-02-03","current":-0.960445,"twenty":-5.583235,"median":-4.443439,"eighty":-2.641266,"marketCap":98374500},{"date":"2023-02-10","current":-0.90484,"twenty":-5.583235,"median":-4.402047,"eighty":-2.609436,"marketCap":92679134},{"date":"2023-02-17","current":-0.8644,"twenty":-5.583235,"median":-4.39207,"eighty":-2.581469,"marketCap":88537050},{"date":"2023-02-24","current":-0.763301,"twenty":-5.583235,"median":-4.365586,"eighty":-2.554574,"marketCap":78181840},{"date":"2023-03-03","current":-0.753191,"twenty":-5.583235,"median":-4.351987,"eighty":-2.49002,"marketCap":77146318},{"date":"2023-03-10","current":-0.748136,"twenty":-5.583235,"median":-4.340393,"eighty":-2.435794,"marketCap":76628558},{"date":"2023-03-17","current":-0.687476,"twenty":-5.569418,"median":-4.315732,"eighty":-2.391745,"marketCap":70415432},{"date":"2023-03-24","current":-0.722861,"twenty":-5.553381,"median":-4.306481,"eighty":-2.317441,"marketCap":74039755},{"date":"2023-03-31","current":-1.642338,"twenty":-5.547029,"median":-4.288241,"eighty":-2.269765,"marketCap":76229128},{"date":"2023-04-06","current":-1.642338,"twenty":-5.547029,"median":-4.263777,"eighty":-2.208281,"marketCap":76229128},{"date":"2023-04-14","current":-1.936826,"twenty":-5.538381,"median":-4.208866,"eighty":-2.122491,"marketCap":89897800},{"date":"2023-04-21","current":-1.902847,"twenty":-5.538381,"median":-4.199845,"eighty":-1.995117,"marketCap":88320645},{"date":"2023-04-28","current":-2.016112,"twenty":-5.538381,"median":-4.167033,"eighty":-1.97096,"marketCap":93577827},{"date":"2023-05-05","current":-2.129376,"twenty":-5.538381,"median":-4.134222,"eighty":-1.959479,"marketCap":98835008},{"date":"2023-05-12","current":-2.174682,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":100937880},{"date":"2023-05-19","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-05-26","current":-3.426213,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":92000672},{"date":"2023-06-02","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-09","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-16","current":-3.073803,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":82537746},{"date":"2023-06-23","current":-2.878019,"twenty":-5.538748,"median":-4.106805,"eighty":-1.959479,"marketCap":77280565},{"date":"2023-06-30","current":-2.780127,"twenty":-5.538932,"median":-4.088313,"eighty":-1.959479,"marketCap":74651974},{"date":"2023-07-07","current":-2.799705,"twenty":-5.535376,"median":-4.066769,"eighty":-1.959479,"marketCap":75177692},{"date":"2023-07-14","current":-2.975911,"twenty":-5.533309,"median":-4.057057,"eighty":-1.959479,"marketCap":79909155},{"date":"2023-07-21","current":-2.858441,"twenty":-5.533309,"median":-4.0428,"eighty":-1.959479,"marketCap":76754846},{"date":"2023-07-28","current":-2.721392,"twenty":-5.533309,"median":-4.025839,"eighty":-1.959479,"marketCap":73074820},{"date":"2023-08-04","current":-2.956332,"twenty":-5.533309,"median":-4.014818,"eighty":-1.959479,"marketCap":79383437},{"date":"2023-08-11","current":-7.559414,"twenty":-5.535376,"median":-4.006786,"eighty":-1.959479,"marketCap":76229128},{"date":"2023-08-18","current":-6.976353,"twenty":-5.547877,"median":-4.006786,"eighty":-1.959479,"marketCap":70349545},{"date":"2023-08-25","current":-6.796031,"twenty":-5.557245,"median":-4.006786,"eighty":-1.959479,"marketCap":68531175},{"date":"2023-09-01","current":-7.841574,"twenty":-5.577899,"median":-4.006786,"eighty":-1.959479,"marketCap":79074433},{"date":"2023-09-08","current":-7.00514,"twenty":-5.590343,"median":-4.006107,"eighty":-1.957214,"marketCap":70639827},{"date":"2023-09-15","current":-6.743754,"twenty":-5.600531,"median":-4.008698,"eighty":-1.954949,"marketCap":68004012},{"date":"2023-09-22","current":-6.377814,"twenty":-5.619353,"median":-4.008698,"eighty":-1.954949,"marketCap":64313872},{"date":"2023-09-27","current":-6.325536,"twenty":-5.635165,"median":-4.007465,"eighty":-1.952683,"marketCap":63786709},{"date":"2023-10-06","current":-6.064151,"twenty":-5.656766,"median":-4.006107,"eighty":-1.948153,"marketCap":61150895},{"date":"2023-10-13","current":-5.855042,"twenty":-5.670432,"median":-4.007465,"eighty":-1.948153,"marketCap":59042243},{"date":"2023-10-20","current":-5.724349,"twenty":-5.700864,"median":-4.017086,"eighty":-1.948153,"marketCap":57724336},{"date":"2023-10-27","current":-5.227716,"twenty":-5.700864,"median":-4.025257,"eighty":-1.940491,"marketCap":52716289},{"date":"2023-11-03","current":-5.959596,"twenty":-5.712838,"median":-4.040427,"eighty":-1.938575,"marketCap":60096569},{"date":"2023-11-10","current":-5.489102,"twenty":-5.718038,"median":-4.056342,"eighty":-1.938575,"marketCap":55352103},{"date":"2023-11-17","current":-38.091206,"twenty":-5.738192,"median":-4.064,"eighty":-1.938225,"marketCap":61479207},{"date":"2023-11-24","current":-39.076324,"twenty":-5.745362,"median":-4.0782,"eighty":-1.938225,"marketCap":63069187},{"date":"2023-12-01","current":-37.434462,"twenty":-5.756595,"median":-4.110221,"eighty":-1.938225,"marketCap":60419221},{"date":"2023-12-08","current":-41.374931,"twenty":-5.775828,"median":-4.143107,"eighty":-1.938575,"marketCap":66779139},{"date":"2023-12-15","current":-42.688421,"twenty":-5.801932,"median":-4.180228,"eighty":-1.938575,"marketCap":68899112},{"date":"2023-12-22","current":-44.658656,"twenty":-5.81944,"median":-4.20788,"eighty":-1.938575,"marketCap":72079071},{"date":"2023-12-29","current":-47.94238,"twenty":-5.826574,"median":-4.262087,"eighty":-1.938225,"marketCap":77379002},{"date":"2024-01-05","current":-48.270753,"twenty":-5.837472,"median":-4.288241,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-01-12","current":-47.94238,"twenty":-5.855042,"median":-4.312399,"eighty":-1.937875,"marketCap":77379002},{"date":"2024-01-19","current":-46.300518,"twenty":-5.879021,"median":-4.328063,"eighty":-1.937526,"marketCap":74729036},{"date":"2024-01-26","current":-51.226105,"twenty":-5.88973,"median":-4.348245,"eighty":-1.937875,"marketCap":82678934},{"date":"2024-02-02","current":-51.554478,"twenty":-5.907523,"median":-4.3779,"eighty":-1.937875,"marketCap":83208927},{"date":"2024-02-09","current":-44.330283,"twenty":-5.93365,"median":-4.402487,"eighty":-1.937875,"marketCap":71549077},{"date":"2024-02-16","current":-49.912615,"twenty":-5.959596,"median":-4.448819,"eighty":-1.937875,"marketCap":80558961},{"date":"2024-02-23","current":-48.270753,"twenty":-5.960111,"median":-4.478613,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-03-01","current":-54.181458,"twenty":-5.982254,"median":-4.491224,"eighty":-1.938225,"marketCap":87448873},{"date":"2024-03-08","current":-56.808437,"twenty":-6.011873,"median":-4.516354,"eighty":-1.938225,"marketCap":91688818},{"date":"2024-03-15","current":4.043621,"twenty":-6.022006,"median":-4.491224,"eighty":-1.934561,"marketCap":92218811},{"date":"2024-03-22","current":4.086364,"twenty":-6.022006,"median":-4.443439,"eighty":-1.853014,"marketCap":93193610},{"date":"2024-03-28","current":4.133605,"twenty":-6.022006,"median":-4.402047,"eighty":-1.811563,"marketCap":94270993},{"date":"2024-04-05","current":3.991881,"twenty":-6.024673,"median":-4.364031,"eighty":-1.717093,"marketCap":91038844},{"date":"2024-04-12","current":4.039122,"twenty":-6.024673,"median":-4.337431,"eighty":-1.389071,"marketCap":92116227},{"date":"2024-04-19","current":3.473759,"twenty":-6.024673,"median":-4.314454,"eighty":-0.978642,"marketCap":79222546},{"date":"2024-04-26","current":3.379235,"twenty":-6.022006,"median":-4.28696,"eighty":-0.969544,"marketCap":77066831},{"date":"2024-05-03","current":3.804593,"twenty":-6.022006,"median":-4.217087,"eighty":-0.959434,"marketCap":86767551},{"date":"2024-05-10","current":3.993641,"twenty":-6.022006,"median":-4.1681,"eighty":-0.950335,"marketCap":91078982},{"date":"2024-05-17","current":3.615427,"twenty":-6.011873,"median":-4.125993,"eighty":-0.940225,"marketCap":84611835},{"date":"2024-05-24","current":3.408173,"twenty":-6.011873,"median":-4.106805,"eighty":-0.93517,"marketCap":79761475},{"date":"2024-05-31","current":3.275692,"twenty":-6.011873,"median":-4.076207,"eighty":-0.930115,"marketCap":76661027},{"date":"2024-06-07","current":3.24109,"twenty":-6.011873,"median":-4.057326,"eighty":-0.924049,"marketCap":75851227},{"date":"2024-06-14","current":3.137283,"twenty":-6.011873,"median":-4.040347,"eighty":-0.90484,"marketCap":73421829},{"date":"2024-06-21","current":3.160351,"twenty":-5.999311,"median":-4.018,"eighty":-0.890686,"marketCap":73961695},{"date":"2024-06-28","current":2.998873,"twenty":-5.968154,"median":-4.008698,"eighty":-0.869455,"marketCap":70182630},{"date":"2024-07-05","current":3.021942,"twenty":-5.968154,"median":-3.981712,"eighty":-0.859345,"marketCap":70722497},{"date":"2024-07-12","current":3.264158,"twenty":-5.968154,"median":-3.944784,"eighty":-0.828004,"marketCap":76391094},{"date":"2024-07-19","current":3.229556,"twenty":-5.968154,"median":-3.912953,"eighty":-0.80374,"marketCap":75581294},{"date":"2024-07-26","current":3.310295,"twenty":-5.968154,"median":-3.884344,"eighty":-0.766334,"marketCap":77470826},{"date":"2024-08-02","current":3.021942,"twenty":-5.968154,"median":-3.86993,"eighty":-0.754532,"marketCap":70722497},{"date":"2024-08-09","current":3.9635,"twenty":-5.968154,"median":-3.8435,"eighty":-0.748136,"marketCap":69182897},{"date":"2024-08-16","current":3.684817,"twenty":-5.968154,"median":-3.802944,"eighty":-0.731947,"marketCap":64318475},{"date":"2024-08-23","current":4.242184,"twenty":-5.968154,"median":-3.776619,"eighty":-0.710729,"marketCap":74047320},{"date":"2024-08-30","current":4.242184,"twenty":-5.968154,"median":-3.739249,"eighty":-0.687476,"marketCap":74047320},{"date":"2024-09-06","current":4.071877,"twenty":-5.968154,"median":-3.72386,"eighty":-0.673679,"marketCap":71074617},{"date":"2024-09-13","current":4.242184,"twenty":-5.968154,"median":-3.704824,"eighty":-0.639964,"marketCap":74047320},{"date":"2024-09-20","current":4.118324,"twenty":-5.968154,"median":-3.66463,"eighty":-0.624838,"marketCap":71885354},{"date":"2024-09-27","current":4.056395,"twenty":-5.968154,"median":-3.621997,"eighty":-0.619173,"marketCap":70804372},{"date":"2024-10-04","current":4.02543,"twenty":-5.968154,"median":-3.580748,"eighty":-0.611743,"marketCap":70263880},{"date":"2024-10-11","current":3.870606,"twenty":-5.968154,"median":-3.543016,"eighty":-0.608647,"marketCap":67561423},{"date":"2024-10-18","current":3.9635,"twenty":-5.968154,"median":-3.524105,"eighty":-0.598121,"marketCap":69182897},{"date":"2024-10-25","current":4.118324,"twenty":-5.968154,"median":-3.504311,"eighty":-0.580785,"marketCap":71885354},{"date":"2024-11-01","current":3.653852,"twenty":-5.968154,"median":-3.483269,"eighty":-0.498231,"marketCap":63777984},{"date":"2024-11-08","current":4.08736,"twenty":-5.968154,"median":-3.473356,"eighty":-0.412966,"marketCap":71344863},{"date":"2024-11-15","current":18.312392,"twenty":-5.968154,"median":-3.457398,"eighty":-0.380514,"marketCap":64331434},{"date":"2024-11-22","current":18.002013,"twenty":-5.968154,"median":-3.43318,"eighty":-0.355643,"marketCap":63241071},{"date":"2024-11-29","current":17.691633,"twenty":-5.968154,"median":-3.425188,"eighty":-0.337997,"marketCap":62150708},{"date":"2024-12-06","current":18.157203,"twenty":-5.968154,"median":-3.411422,"eighty":-0.328336,"marketCap":63786253},{"date":"2024-12-13","current":16.605305,"twenty":-5.968154,"median":-3.386446,"eighty":-0.310608,"marketCap":58334436},{"date":"2024-12-20","current":14.822174,"twenty":-5.968154,"median":-3.366798,"eighty":-0.299066,"marketCap":52070299},{"date":"2024-12-27","current":15.984546,"twenty":-5.968154,"median":-3.345345,"eighty":-0.294623,"marketCap":56153709},{"date":"2025-01-03","current":17.070874,"twenty":-5.968154,"median":-3.32835,"eighty":-0.282151,"marketCap":59969981},{"date":"2025-01-10","current":15.208597,"twenty":-5.972143,"median":-3.295829,"eighty":-0.27794,"marketCap":53427801},{"date":"2025-01-17","current":14.122269,"twenty":-5.972143,"median":-3.259228,"eighty":-0.270436,"marketCap":49611530},{"date":"2025-01-24","current":13.465816,"twenty":-5.972143,"median":-3.242754,"eighty":-0.26267,"marketCap":47305411},{"date":"2025-01-31","current":13.293555,"twenty":-5.972143,"median":-3.215126,"eighty":-0.252501,"marketCap":46700260},{"date":"2025-02-07","current":12.70073,"twenty":-5.972143,"median":-3.176076,"eighty":-0.248282,"marketCap":44617666},{"date":"2025-02-14","current":12.647966,"twenty":-5.972143,"median":-3.155249,"eighty":-0.245362,"marketCap":44432304},{"date":"2025-02-21","current":12.89627,"twenty":-5.972143,"median":-3.131939,"eighty":-0.243796,"marketCap":45304595},{"date":"2025-02-28","current":12.036518,"twenty":-5.972143,"median":-3.117302,"eighty":-0.239832,"marketCap":42284288},{"date":"2025-03-07","current":12.089283,"twenty":-5.976133,"median":-3.105192,"eighty":-0.225795,"marketCap":42469650},{"date":"2025-03-14","current":12.142047,"twenty":-5.976133,"median":-3.09377,"eighty":2.948123,"marketCap":42655012},{"date":"2025-03-21","current":12.759703,"twenty":-5.976133,"median":-3.09377,"eighty":3.021942,"marketCap":44824835},{"date":"2025-03-28","current":-0.624914,"twenty":-5.976133,"median":-3.09377,"eighty":3.068078,"marketCap":42847841},{"date":"2025-04-04","current":-0.474494,"twenty":-5.976133,"median":-3.09377,"eighty":3.068078,"marketCap":32534173},{"date":"2025-04-11","current":-0.489169,"twenty":-5.972143,"median":-3.092168,"eighty":3.068078,"marketCap":33540384},{"date":"2025-04-17","current":-0.614886,"twenty":-5.972143,"median":-3.092168,"eighty":3.068078,"marketCap":42160263},{"date":"2025-04-25","current":-0.591243,"twenty":-5.976133,"median":-3.09377,"eighty":3.068078,"marketCap":40539144},{"date":"2025-05-02","current":-0.527582,"twenty":-5.976133,"median":-3.075476,"eighty":3.068078,"marketCap":36174184},{"date":"2025-05-09","current":-0.505565,"twenty":-5.976133,"median":-3.045909,"eighty":3.068078,"marketCap":34664597},{"date":"2025-05-16","current":-0.521735,"twenty":-5.976133,"median":-3.016378,"eighty":3.068078,"marketCap":36397827},{"date":"2025-05-23","current":-0.559403,"twenty":-5.976133,"median":-2.968777,"eighty":3.068078,"marketCap":39025627},{"date":"2025-05-30","current":-1.707061,"twenty":-5.976133,"median":-2.956332,"eighty":3.068078,"marketCap":119089665},{"date":"2025-06-06","current":-2.051678,"twenty":-5.976133,"median":-2.924352,"eighty":3.068078,"marketCap":143131240},{"date":"2025-06-13","current":-2.316153,"twenty":-5.976133,"median":-2.884093,"eighty":3.068078,"marketCap":161581752},{"date":"2025-06-20","current":-2.356224,"twenty":-5.980122,"median":-2.858441,"eighty":3.068078,"marketCap":164377284},{"date":"2025-06-27","current":-2.324167,"twenty":-5.980122,"median":-2.838862,"eighty":3.068078,"marketCap":162140858},{"date":"2025-07-03","current":-2.332181,"twenty":-5.980122,"median":-2.780127,"eighty":3.068078,"marketCap":162699965},{"date":"2025-07-11","current":-2.276081,"twenty":-5.980122,"median":-2.754884,"eighty":3.068078,"marketCap":158786220},{"date":"2025-07-18","current":-1.987563,"twenty":-5.980122,"median":-2.664062,"eighty":3.068078,"marketCap":138658389},{"date":"2025-07-25","current":-1.883377,"twenty":-5.980122,"median":-2.492541,"eighty":3.068078,"marketCap":131390006},{"date":"2025-08-01","current":-1.859334,"twenty":-5.980122,"median":-2.383059,"eighty":3.068078,"marketCap":129712687},{"date":"2025-08-08","current":-1.739118,"twenty":-5.980122,"median":-2.350214,"eighty":3.068078,"marketCap":121326090},{"date":"2025-08-15","current":-2.065317,"twenty":-5.980122,"median":-2.324167,"eighty":3.068078,"marketCap":110703069},{"date":"2025-08-22","current":-1.952798,"twenty":-5.980122,"median":-2.324167,"eighty":3.068078,"marketCap":104671918},{"date":"2025-08-29","current":-2.099783,"twenty":-5.980122,"median":-2.284095,"eighty":3.068078,"marketCap":112550450},{"date":"2025-09-05","current":-2.246767,"twenty":-5.980399,"median":-2.249403,"eighty":3.068078,"marketCap":120428981},{"date":"2025-09-12","current":-2.047288,"twenty":-5.980122,"median":-2.211966,"eighty":3.068078,"marketCap":109736688},{"date":"2025-09-19","current":-2.099783,"twenty":-5.980122,"median":-2.174682,"eighty":3.068078,"marketCap":112550450},{"date":"2025-09-26","current":-2.036789,"twenty":-5.980122,"median":-2.152029,"eighty":3.068078,"marketCap":109173936},{"date":"2025-10-03","current":-2.131279,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":114238706},{"date":"2025-10-10","current":-2.477744,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":132809531},{"date":"2025-10-17","current":-2.467245,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":132246778},{"date":"2025-10-24","current":-2.309761,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":123805495},{"date":"2025-10-31","current":-2.477744,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":132809531},{"date":"2025-11-07","current":-2.50924,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":134497787},{"date":"2025-11-14","current":-2.561735,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":137311549},{"date":"2025-11-21","current":-2.904617,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":127326806},{"date":"2025-11-28","current":-3.084549,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":135214308},{"date":"2025-12-05","current":-2.930322,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":128453592},{"date":"2025-12-12","current":-3.020288,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":132397343},{"date":"2025-12-19","current":-2.943174,"twenty":-5.980122,"median":-2.129376,"eighty":3.068078,"marketCap":129016985},{"date":"2025-12-26","current":-3.007436,"twenty":-5.959596,"median":-2.129376,"eighty":3.068078,"marketCap":131833950},{"date":"2026-01-02","current":-2.994583,"twenty":-5.932512,"median":-2.129376,"eighty":3.068078,"marketCap":131270557},{"date":"2026-01-09","current":-3.303038,"twenty":-5.932512,"median":-2.129376,"eighty":3.068078,"marketCap":144791988},{"date":"2026-01-16","current":-3.084549,"twenty":-5.932512,"median":-2.129376,"eighty":3.068078,"marketCap":135214308},{"date":"2026-01-23","current":-3.148811,"twenty":-5.917492,"median":-2.129376,"eighty":3.068078,"marketCap":138031272},{"date":"2026-01-30","current":-2.891765,"twenty":-5.907319,"median":-2.129376,"eighty":3.068078,"marketCap":126763413},{"date":"2026-02-05","current":-2.943174,"twenty":-5.888463,"median":-2.129376,"eighty":3.068078,"marketCap":129016985}],"updateTime":1770406430202},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607247180","title":"Spero Therapeutics CEO Ankit Mahadevia Resigns Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607247180","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607247180?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:01","pubTimestamp":1769810512,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. announced that Ankit Mahadevia, MD will resign from the Board of Directors, the Development Committee, and all officer and director roles with the company and its subsidiaries, effective January 30, 2026. Dr. Mahadevia will enter into a consulting agreement to provide support to the company's management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL358KgD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"gpt_icon":0},{"id":"2592620561","title":"Spero Therapeutics to Receive $25 Million Milestone Payment Following Tebipenem HBr NDA Resubmission by GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2592620561","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592620561?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:26","pubTimestamp":1766150774,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. announced that its development partner, GlaxoSmithKline Intellectual Property  Limited , has filed a New Drug Application  resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis. The NDA resubmission triggers a $25 million milestone payment to Spero Therapeutics under its License Agreement with GSK, which is expected to be received in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLQgcjQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU1481599808.USD","LU0289739699.SGD","LU1046248800.SGD","LU1035777561.USD","LU0971552830.HKD","LU1064927863.SGD","LU1487256676.USD","LU1645745479.HKD","LU0225771236.USD","IE00BQJZX424.USD","LU0109981661.USD","LU0203345920.USD","LU0058720904.USD","LU1400636574.HKD","LU0321505439.SGD","LU1098665638.USD","LU1400636657.SGD","LU1481600234.SGD","BK5011","GSK.UK","LU0985481810.HKD","LU0161305163.EUR","LU0306807586.USD","LU0306806265.USD","LU1302929846.USD","BK4139","LU1309081286.SGD","IE00B3T34201.USD","LU1228905540.USD","LU1670756490.USD","IE0034235071.USD","IE00BWDBJ516.SGD","LU1202635105.USD","LU0211331839.USD","LU1015430645.USD","LU0545562505.USD","LU0203347892.USD","LU0971552673.USD","LU1400636491.USD","LU0575583348.USD","SPRO","LU1228905037.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2592628101","title":"Spero Therapeutics Announces FDA Review of Tebipenem HBr NDA Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2592628101","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592628101?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:00","pubTimestamp":1766149221,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. announced that its partner, GSK, has resubmitted a New Drug Application  to the U.S. Food and Drug Administration  for tebipenem HBr, an investigational oral carbapenem antibiotic for the treatment of complicated urinary tract infections , including pyelonephritis. The NDA resubmission follows positive results from the Phase 3 PIVOT-PO trial. This regulatory review triggers a $25 million milestone payment to Spero, expected in the first quarter of 2026. Select studies of tebipenem HBr have also received partial funding from federal agencies, including the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5NLpZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","SPRO","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2592628611","title":"Spero Therapeutics Inc - Nda Submission Triggers $25 Mln Milestone Payment to Spero","url":"https://stock-news.laohu8.com/highlight/detail?id=2592628611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592628611?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:00","pubTimestamp":1766149202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA8BRWC0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1400636574.HKD","BK4139","LU0321505439.SGD","LU1228905540.USD","LU1645745479.HKD","LU1670756490.USD","LU1302929846.USD","LU0109981661.USD","LU0225771236.USD","LU1015430645.USD","LU1202635105.USD","LU1098665638.USD","LU1309081286.SGD","LU0058720904.USD","LU1035777561.USD","LU0306806265.USD","LU1481599808.USD","GSK.UK","LU1400636657.SGD","LU1228905037.USD","LU1064927863.SGD","LU0289739699.SGD","BK5011","IE00B3T34201.USD","LU1481600234.SGD","LU0545562505.USD","LU0203345920.USD","IE00BWDBJ516.SGD","IE0034235071.USD","LU0971552673.USD","LU0985481810.HKD","LU1487256676.USD","LU0321505868.SGD","SPRO","IE00BQJZX424.USD","LU0971552830.HKD","LU1046248800.SGD","LU0203347892.USD","LU0211331839.USD","LU0306807586.USD","LU0161305163.EUR","LU0575583348.USD","LU0225284248.USD","LU1400636491.USD"],"gpt_icon":0},{"id":"2592162853","title":"Spero Announces Nda Resubmission of Tebipenem Hbr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162853?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:00","pubTimestamp":1766149202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA8BRWC0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRO","BK4139"],"gpt_icon":0},{"id":"2586876037","title":"Spero Therapeutics announces inducement grant under Nasdaq listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2586876037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586876037?lang=en_us&edition=fundamental","pubTime":"2025-11-28 21:10","pubTimestamp":1764335422,"startTime":"0","endTime":"0","summary":"Spero Therapeutics (SPRO) announced that on November 3, 2025, the Compensation Committee of Spero’s Board of Directors approved the grant of an agg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","USJW.SI","TQQQ","BK4007","NVIW.SI",".IXIC","NQmain","QLD","PSQ","SQQQ","BK4139","QID","TSYW.SI","SPRO","USAW.SI","MNQmain"],"gpt_icon":0},{"id":"2586782769","title":"Spero Therapeutics Grants 90,000 RSUs to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782769?lang=en_us&edition=fundamental","pubTime":"2025-11-28 21:00","pubTimestamp":1764334810,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. has granted 90,000 restricted stock unit awards  to a new employee under its 2019 Inducement Equity Incentive Plan. The RSUs will vest in four equal annual installments beginning on December 1, 2025, contingent on the employee's continued employment with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL52QTmw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","SPRO","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2583512641","title":"Spero Therapeutics Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512641","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512641?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:24","pubTimestamp":1763069052,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Q3 net loss narrowsOverviewSpero Q3 net loss narrowsSpero expects cash reserves to fund operations into 2028OutlookSpero expects cash reserves to fund operations into 2028Result Dri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP18P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"gpt_icon":0},{"id":"2583884514","title":"BRIEF-Spero Therapeutics Q3 EPS USD -0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2583884514","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583884514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067949,"startTime":"0","endTime":"0","summary":"BRIEF-Spero Therapeutics Q3 EPS USD -0.13\n\n\nNov 13 (Reuters) - Spero Therapeutics Q3 operating expenses USD 13.358 million.\n\nQ3 income from operation USD -7.916 million\nQ3 net income USD -7.382 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX8739F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"gpt_icon":0},{"id":"2583511250","title":"Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511250?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067904,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA240WZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRO"],"gpt_icon":0},{"id":"2577843740","title":"Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577843740","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577843740?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026448,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. and GSK plc have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections , including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL7vv9hM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SPRO","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2577484595","title":"BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr","url":"https://stock-news.laohu8.com/highlight/detail?id=2577484595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577484595?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026407,"startTime":"0","endTime":"0","summary":"BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBrOct 21  - GSK plc GSK.L & Spero Therapeutics SPRO.O :GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBRGSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR  COMPLICATED URINARY TRACT INFECTIONSGSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENTGSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICSGSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4Source text: [ID:]Further company coverage: GSK.L ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE00BQJZX424.USD","LU0971552673.USD","IE0034235071.USD","LU1015430645.USD","LU0306807586.USD","LU1481600234.SGD","LU1670756490.USD","BK4139","LU0058720904.USD","LU1046248800.SGD","LU1202635105.USD","SPRO","LU1645745479.HKD","LU1487256676.USD","LU0575583348.USD","LU0971552830.HKD","LU1228905540.USD","LU1064927863.SGD","LU0225771236.USD","LU0203345920.USD","GSK.UK","LU0985481810.HKD","LU1228905037.USD","LU1309081286.SGD","LU1400636574.HKD","LU0545562505.USD","LU1400636491.USD","LU1302929846.USD","BK5011","LU0161305163.EUR","LU0203347892.USD","LU1400636657.SGD","IE00BWDBJ516.SGD","LU0211331839.USD","LU0321505439.SGD","LU0109981661.USD","LU0225284248.USD","LU0306806265.USD","LU1098665638.USD","LU0321505868.SGD","LU1481599808.USD","LU1035777561.USD"],"gpt_icon":0},{"id":"2577843478","title":"GSK: to Work With U.S. Authorities to Include Tebipenem Hbr Data as Part of Filing in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2577843478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577843478?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1302929846.USD","LU0321505439.SGD","LU1481599808.USD","LU0203347892.USD","LU1670756490.USD","LU0971552830.HKD","BK5011","LU0211331839.USD","LU0161305163.EUR","LU0321505868.SGD","IE00BQJZX424.USD","LU1064927863.SGD","LU0306806265.USD","LU1400636574.HKD","LU1202635105.USD","LU0058720904.USD","LU0203345920.USD","LU1015430645.USD","IE0034235071.USD","LU0971552673.USD","LU1400636491.USD","LU1228905037.USD","LU1481600234.SGD","LU0109981661.USD","LU0225284248.USD","LU1046248800.SGD","LU0575583348.USD","LU1487256676.USD","LU1228905540.USD","LU1098665638.USD","LU1035777561.USD","LU0289739699.SGD","LU0306807586.USD","LU0545562505.USD","LU0225771236.USD","LU0985481810.HKD","LU1309081286.SGD","IE00BWDBJ516.SGD","LU1400636657.SGD","LU1645745479.HKD","SPRO","GSK.UK"],"gpt_icon":0},{"id":"2577843423","title":"GSK: Data Show Tebipenem Hbr’s Potential as First Oral Carbapenem Antibiotic for  Complicated Urinary Tract Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2577843423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577843423?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1487256676.USD","LU0225284248.USD","LU0225771236.USD","LU1098665638.USD","LU1645745479.HKD","LU0109981661.USD","LU0211331839.USD","LU0971552830.HKD","LU1228905037.USD","LU1046248800.SGD","LU0985481810.HKD","IE0034235071.USD","LU1481599808.USD","LU1400636491.USD","LU0321505868.SGD","LU0545562505.USD","LU0289739699.SGD","LU1302929846.USD","LU1481600234.SGD","LU1670756490.USD","LU1064927863.SGD","BK5011","LU0161305163.EUR","LU0321505439.SGD","LU0575583348.USD","IE00BWDBJ516.SGD","LU1228905540.USD","IE00BQJZX424.USD","LU1035777561.USD","LU0306807586.USD","GSK.UK","LU1400636657.SGD","LU0203345920.USD","LU1015430645.USD","LU0058720904.USD","LU0306806265.USD","LU1400636574.HKD","LU0971552673.USD","LU0203347892.USD","LU1202635105.USD","SPRO","LU1309081286.SGD"],"gpt_icon":0},{"id":"2577843401","title":"GSK: Full Results of Positive Pivotal Phase Iii Pivot-Po Trial Evaluating Tebipenem Hbr","url":"https://stock-news.laohu8.com/highlight/detail?id=2577843401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577843401?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1098665638.USD","LU1202635105.USD","LU1228905540.USD","LU0575583348.USD","BK4139","IE0034235071.USD","LU1670756490.USD","LU0203347892.USD","LU1015430645.USD","LU1309081286.SGD","LU1400636574.HKD","IE00BQJZX424.USD","LU1035777561.USD","BK5011","LU0321505439.SGD","LU0985481810.HKD","LU0225284248.USD","LU0203345920.USD","LU1302929846.USD","IE00BWDBJ516.SGD","GSK.UK","LU0971552830.HKD","LU1064927863.SGD","LU0545562505.USD","LU0211331839.USD","LU0058720904.USD","LU0225771236.USD","LU0161305163.EUR","LU1400636657.SGD","LU1481599808.USD","LU0306806265.USD","LU1645745479.HKD","LU1481600234.SGD","LU1228905037.USD","LU1400636491.USD","LU0109981661.USD","LU1046248800.SGD","LU0971552673.USD","SPRO","LU0306807586.USD","LU0321505868.SGD","LU1487256676.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2577434208","title":"GSK: Safety Profile of Tebipenem Hbr Generally Similar to Imipenem-Cilastatin & Other Carbapenem Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577434208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577434208?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1098665638.USD","LU1202635105.USD","LU1228905540.USD","LU0575583348.USD","BK4139","IE0034235071.USD","LU1670756490.USD","LU0203347892.USD","LU1015430645.USD","LU1309081286.SGD","LU1400636574.HKD","IE00BQJZX424.USD","LU1035777561.USD","BK5011","LU0321505439.SGD","LU0985481810.HKD","LU0225284248.USD","LU0203345920.USD","LU1302929846.USD","IE00BWDBJ516.SGD","GSK.UK","LU0971552830.HKD","LU1064927863.SGD","LU0545562505.USD","LU0211331839.USD","LU0058720904.USD","LU0225771236.USD","LU0161305163.EUR","LU1400636657.SGD","LU1481599808.USD","LU0306806265.USD","LU1645745479.HKD","LU1481600234.SGD","LU1228905037.USD","LU1400636491.USD","LU0109981661.USD","LU1046248800.SGD","LU0971552673.USD","SPRO","LU0306807586.USD","LU0321505868.SGD","LU1487256676.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2577239843","title":"GSK: Trial Primary Endpoint Met, Showing Non-Inferiority of Oral Tebipenem Hbr VS Iv Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577239843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577239843?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1487256676.USD","LU0225284248.USD","LU0225771236.USD","LU1098665638.USD","LU1645745479.HKD","LU0109981661.USD","LU0211331839.USD","LU0971552830.HKD","LU1228905037.USD","LU1046248800.SGD","LU0985481810.HKD","IE0034235071.USD","LU1481599808.USD","LU1400636491.USD","LU0321505868.SGD","LU0545562505.USD","LU0289739699.SGD","LU1302929846.USD","LU1481600234.SGD","LU1670756490.USD","LU1064927863.SGD","BK5011","LU0161305163.EUR","LU0321505439.SGD","LU0575583348.USD","IE00BWDBJ516.SGD","LU1228905540.USD","IE00BQJZX424.USD","LU1035777561.USD","LU0306807586.USD","GSK.UK","LU1400636657.SGD","LU0203345920.USD","LU1015430645.USD","LU0058720904.USD","LU0306806265.USD","LU1400636574.HKD","LU0971552673.USD","LU0203347892.USD","LU1202635105.USD","SPRO","LU1309081286.SGD"],"gpt_icon":0},{"id":"2575972682","title":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575972682","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575972682?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:01","pubTimestamp":1760443260,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025. Spero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections , including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.Disclaimer: This news brief was created ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbfDNkx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","SPRO","BK4588"],"gpt_icon":0},{"id":"2564936444","title":"Director Ankit Mahadevia Reports Disposal of Common Shares of Spero Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2564936444","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564936444?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:14","pubTimestamp":1756894498,"startTime":"0","endTime":"0","summary":"Ankit Mahadevia, a Director of Spero Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4Cs1sW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"gpt_icon":0},{"id":"2564464364","title":"Timothy Keutzer, Chief Operating Officer, Reports Disposal of Spero Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2564464364","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564464364?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:14","pubTimestamp":1756894498,"startTime":"0","endTime":"0","summary":"Timothy Keutzer, Chief Operating Officer of Spero Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL6zVyQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}